特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
682157

肉腫治療薬市場規模、シェア、動向分析:治療タイプ別(化学療法、標的療法)、主要市場別(米国、英国、ドイツ、スペイン、イタリア、フランス、日本)、セグメント予測(2018~2023年)

Sarcoma Drugs Market Size, Share & Trends Analysis Report By Treatment Type (Chemotherapy, Targeted Therapy), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2018 - 2023

出版日: | 発行: Grand View Research, Inc. | ページ情報: 英文 93 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
肉腫治療薬市場規模、シェア、動向分析:治療タイプ別(化学療法、標的療法)、主要市場別(米国、英国、ドイツ、スペイン、イタリア、フランス、日本)、セグメント予測(2018~2023年)
出版日: 2018年07月17日
発行: Grand View Research, Inc.
ページ情報: 英文 93 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の肉腫治療薬市場規模は2023年までに12億米ドルに達すると予測されています。新製品の上市や新たな治療法の普及、標的人口の増加が市場の成長を牽引しています。

当レポートでは、世界の肉腫治療薬市場について調査し、市場の現状と2023年までの成長予測、治療タイプ別、主要市場別動向、および市場に参入する企業のプロファイルなどをまとめています。

第1章 調査方法

第2章 エグゼクティブサマリー

第3章 疾患概要と疫学

  • 疾患概要
    • 軟部組織肉腫
    • 骨肉種
    • 現在の7大市場における罹患率と発症率

第4章 市場概要

  • 市場概要
  • 治療別市場
  • 市場規模と予測
  • 7大市場における市場規模と予測
  • 企業別市場シェア分布
  • 市場動向とブランド戦略
  • 特許失効分析
  • 促進因子と阻害因子
  • M&A、取引動向
  • 価格設定と償還シナリオ
  • SWOT分析

第5章 パイプラインインテリジェンス

  • パイプライン環境
  • 主な研究開発動向
  • パイプライン環境
  • 破壊的薬剤の臨床プロファイル
  • 世界のパイプライン予測

第6章 企業プロファイル

  • Novartis
  • Pfizer
  • Eli Lilly
  • エーザイ株式会社
  • Johnson & Johnson
  • Bayer

第7章 市場見通し

図表

List of Tables

  • TABLE 1 Sarcoma - Classification
  • TABLE 2 Soft-Tissue Sarcoma - Staging and Five-Year Survival Rate
  • TABLE 3 Bone Sarcoma - Staging and Five-Year Survival Rate
  • TABLE 4 First-line Chemotherapy for Sarcoma (Generics)
  • TABLE 5 Marketed Drugs for Sarcoma
  • TABLE 6 Sales by Treatment Type, in $ Million, 2017 - 2023
  • TABLE 7 Sales Performance by Country, in $ Million, 2017 - 2023
  • TABLE 8 U.S., Sales by Treatment Type (2017 - 2023)
  • TABLE 9 U.K., Sales by Treatment Type (2017 - 2023)
  • TABLE 10 Germany, Sales by Treatment Type (2017 - 2023)
  • TABLE 11 France, Sales by Treatment Type (2017 - 2023)
  • TABLE 12 Italy, Sales by Treatment Type (2017 - 2023)
  • TABLE 13 Spain, Sales by Treatment Type (2017 - 2023)
  • TABLE 14 Japan, Sales by Treatment Type (2017 - 2023)
  • TABLE 15 Patent Expiry Analysis
  • TABLE 16 R&D Pipeline Overview - Leading Drugs
  • TABLE 17 Late Stage Pipeline Analysis
  • TABLE 18 BLU-285 (avapritinib)
  • TABLE 19 INNO-206 (Aldoxorubicin)
  • TABLE 20 TRC105 (carotuximab)
  • TABLE 21 Pipeline Forecast
  • TABLE 22 Novartis Product Forecast Sales (2017 - 2023)
  • TABLE 23 Pfizer Product Forecast Sales (2017 - 2023)
  • TABLE 24 Eli Lilly Product Forecast Sales (2017 - 2023)
  • TABLE 25 Eisai - Product Forecast Sales (2017 - 2023)
  • TABLE 26 Johnson & Johnson Product Forecast Sales (2017 - 2023)
  • TABLE 27 Bayer Product Forecast Sales (2017 - 2023)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information Procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Sarcoma Major Subtypes
  • FIG. 8 U.S. - Soft Tissue Sarcoma Incidence and Mortality Trends
  • FIG. 9 U.S. - Bone Sarcoma Incidence and Mortality Trends
  • FIG. 10 U.K.- STS Incidence Rates per 100,000 Population, by Sex
  • FIG. 11 U.K.-Bone Sarcoma Incidence Rates per 100,000 Population, by Sex
  • FIG. 12 Germany- Sarcoma Incidence and Mortality Trends
  • FIG. 13 Germany- Age-Standardized Incidence Rate per 100,000 people
  • FIG. 14 France - STS Age-Standardized Incidence Rate per 100,000 people
  • FIG. 15 Japan - Sarcoma Incidence Trends
  • FIG. 16 Treatment Type, Market Share Distribution, 2017 and 2023
  • FIG. 17 Regional Market Size, 2017 & 2023
  • FIG. 18 Market Shares Distribution, by Company (2017 & 2023)
  • FIG. 19 Sarcoma Sector SWOT
  • FIG. 20 Sarcoma R&D Pipeline - Drugs in Development
  • FIG. 21 Sarcoma R&D Pipeline, by Treatment Type
  • FIG. 22 Immunotherapy Types In Development for Sarcoma Treatment
  • FIG. 23 Novartis Sarcoma Sales Forecast
  • FIG. 24 Novartis SWOT Analysis
  • FIG. 25 Pfizer Sarcoma Sales Forecast
  • FIG. 26 Pfizer SWOT Analysis
  • FIG. 27 Eli Lilly Sarcoma Sales Forecast
  • FIG. 28 Eli Lilly SWOT Analysis
  • FIG. 29 Eisai Sarcoma Sales Forecast
  • FIG. 30 Eisai SWOT Analysis
  • FIG. 31 Johnson & Johnson Sarcoma Sales Forecast
  • FIG. 32 Johnson & Johnson SWOT Analysis
  • FIG. 33 Bayer Sarcoma Sales Forecast
  • FIG. 34 Bayer SWOT Analysis
目次
Product Code: GVR-2-68038-528-1

The global sarcoma drugs market size is expected to be valued at USD 1.2 billion by 2023, as per a new report by Grand View Research, Inc., progressing at a CAGR of 8.5% during the forecast period. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. Introduction of targeted therapy has revolutionized treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

Further key findings from the report suggest:

EU5 will remain the second largest market with more than 30% share by 2023. The growth of the segment can be attributed to rising incidence of STS, uptake of targeted therapies, and increasing R&D activities

  • Eli Lilly's Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period
  • Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials
  • The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials
  • Companies with late-stage pipeline products for sarcoma are likely to enter the market by 2019 and would capture more than 10.0% of the sarcoma market share in 2023
  • Drugs with novel targets in early-phase development include Novartis's Afinitor (mTOR inhibitor), Tesaro's Zejula (PARP inhibitor), Amgen's Imlygic (gene therapy), and Pfizer's Crizotinib (ALK and MET tyrosine kinases inhibitor)
  • Role of VEGF inhibitors and mTOR inhibitors is under evaluation in multiple early phase trials. However, no statistically significant data has been reported till date

Table of Contents

Chapter 1 Research Methodology

  • 1.1. Information procurement
  • 1.2. Information or Data Analysis
    • 1.2.1. Market Formulation & Validation

Chapter 2 Executive Summary

Chapter 3 Disease Primer and Epidemiology

  • 3.1 Disease Primer
    • 3.1.1 Soft Tissue Sarcoma (STS)
    • 3.1.2 Bone Sarcoma
    • 3.1.3 Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S.,Japan,EU5)

Chapter 4 Global Sarcoma Drugs Market Overview

  • 4.1 Sarcoma Drugs Market Overview
    • 4.1.1 Tyrosine kinase inhibitors (c-KIT, PDGFR, and VEGF inhibitors)
    • 4.1.2 Cell Cycle Inhibitors
    • 4.1.3 mTOR inhibitors
  • 4.2 Market, by Treatment Type
  • 4.3 Market Size and Forecast (2017 - 2023)
  • 4.4 Market Size and Forecast, by Seven Major Markets (2017 - 2023)
    • 4.4.1 U.S. Sales by Treatment Type (2017 - 2023)
    • 4.4.2 U.K. Sales by Treatment Type (2017 - 2023)
    • 4.4.3 Germany Sales by Treatment Type (2017 - 2023)
    • 4.4.4 France Sales by Treatment Type (2017 - 2023)
    • 4.4.5 Italy Sales by Treatment Type (2017 - 2023)
    • 4.4.6 Spain Sales by Treatment Type (2017 - 2023)
    • 4.4.7 Japan Sales by Treatment Type (2017 - 2023)
  • 4.5 Market Share Distribution, by Company (2017 - 2023)
  • 4.6 Market Dynamics and Brand Strategies
  • 4.7 Patent Expiry Analysis
  • 4.8 Sarcoma Drugs Market: Drivers and Restraints
    • 4.8.1 Market Drivers
    • 4.8.2 Market Restraints
  • 4.9 M&A, Deal Landscape (2013-2018 YTD)
    • 4.9.1 Mergers & Acquisitions
    • 4.9.2 Deals Landscape
  • 4.10 Pricing and Reimbursement Scenario
  • 4.11 Sarcoma Sector SWOT

Chapter 5 Sarcoma Drugs Market: Pipeline Intelligence

  • 5.1 Pipeline Landscape
    • 5.1.1 Leading Drugs in Development
  • 5.2 Key R&D Trends
    • 5.2.1 Chemotherapy
    • 5.2.2 Targeted Therapy
    • 5.2.3 Immunotherapy
      • 5.2.3.1 Immuno-oncology agents
      • 5.2.3.2 Cancer Vaccines
      • 5.2.3.3 Gene Therapy
  • 5.3 Pipeline Landscape
    • 5.3.1 Late Stage Pipeline Drugs
  • 5.4 Clinical Profiles of Disruptive Drugs
  • 5.5 Global Pipeline Forecast

Chapter 6 Company Profiles

  • 6.1 Novartis
    • 6.1.1 Company Overview
    • 6.1.2 Product Portfolio
    • 6.1.3 Product Forecast Sales through 2023
    • 6.1.4 Strategic Initiatives
      • 6.1.4.1 Key Company News Flow
    • 6.1.5 Pipeline Analysis and Overview
    • 6.1.6 SWOT
  • 6.2 Pfizer
    • 6.2.1 Company Overview
    • 6.2.2 Product Portfolio
    • 6.2.3 Product Forecast Sales through 2023
    • 6.2.4 Strategic Initiatives
      • 6.2.4.1 Key Company News Flow
    • 6.2.5 Pipeline Analysis and Overview
    • 6.2.6 SWOT
  • 6.3 Eli Lilly
    • 6.3.1 Company Overview
    • 6.3.2 Current Product Portfolio
    • 6.3.3 Product Forecast Sales through 2023
    • 6.3.4 Strategic Initiatives
      • 6.3.4.1 Key Company News Flow
      • 6.3.4.2 Catalysts & Events Calendar
    • 6.3.5 Pipeline Analysis and Overview
    • 6.3.6 SWOT
  • 6.4 Eisai
    • 6.4.1 Company Overview
    • 6.4.2 Product Portfolio
    • 6.4.3 Product Forecast Sales through 2023
    • 6.4.4 Strategic Initiatives
      • 6.4.4.1 Key Company News Flow
    • 6.4.5 Pipeline Analysis and Overview
    • 6.4.6 SWOT
  • 6.5 Johnson & Johnson
    • 6.5.1 Company Overview
    • 6.5.2 Product Portfolio
    • 6.5.3 Product Forecast Sales through 2023
    • 6.5.4 Strategic Initiatives
      • 6.5.4.1 Key Company News Flow
    • 6.5.5 Pipeline Analysis and Overview
    • 6.5.6 SWOT
  • 6.6 Bayer
    • 6.6.1 Company Overview
    • 6.6.2 Product Portfolio
    • 6.6.3 Product Forecast Sales through 2023
    • 6.6.4 Strategic Initiatives
      • 6.6.4.1 Key Company News Flow
    • 6.6.5 Pipeline Analysis and Overview
    • 6.6.6 SWOT

Chapter 7 Market Outlook

  • 7.1. What the Future Holds
  • 7.2. The Winners and Losers
    • 7.2.1. Winners
    • 7.2.2. Losers
  • 7.3. Emerging Companies/New Technology Platforms
  • 7.4. The Road Ahead
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.